search
Back to results

A Study of the SING IMT in an Israeli Cohort

Primary Purpose

Age-Related Macular Degeneration, Geographic Atrophy

Status
Not yet recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
smaller incision, new generation implantable miniature telescope (SING-IMT)
Sponsored by
VisionCare, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Age-Related Macular Degeneration focused on measuring Implantable Miniature Telescope

Eligibility Criteria

55 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: For Both Eyes: Be at least 55 years of age at the Pre-operative Visit; Have ETDRS BCDVA 0.6 to 1.6 logMAR (20/80 to 20/800) at the Pre-operative Visit; Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by fluorescein angiography (FA) or OCT; Have an Endothelial Cell Density (ECD) above 1800 cells per millimeter; Have central anterior chamber depth (ACD) >2.5 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit; Agree to participate in post-operative visual training For the Implanted Eye: Have evidence of visually significant cataract at the Pre-operative Visit; Agree to undergo pre-operative assessment with low vision specialists (optometrist, occupational therapist or other professional with low vision experience) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment For the Non-Implanted Eye: -Have adequate peripheral vision at the Pre-operative Visit to allow navigation. Exclusion Criteria: For Both Eyes: Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training/rehabilitation with the device; Have evidence of bilateral active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months. Have any of the following conditions at the Pre-operative Visit: Stargardt macular dystrophy; Diabetic retinopathy; Untreated retinal tears; Retinal vascular disease; Optic nerve disease; History of retinal detachment; Intraocular tumor; Retinitis pigmentosa; History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit; Have known allergy to post-operative medications; History of eye rubbing or an ocular condition that predisposes subject to eye rubbing; Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit; Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety; Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study; Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit. For the Implanted Eye: Have a history of corneal stromal or endothelial dystrophies, including guttata; Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit; Have an Axial Length (AL) < 21 mm at the Pre-operative Visit; Have a narrow angle defined as < grade 2 on the Schaffer scale at the Pre-operative Visit; Ongoing Inflammatory ocular disease at the Pre-operative Visit; Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit; Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery; Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes; For the Non-Implanted Eye: -Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.

Sites / Locations

  • Wolfson Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Implanted Eye with SING IMT

Arm Description

The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant

Outcomes

Primary Outcome Measures

Safety: Endothelial cell density
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study

Secondary Outcome Measures

Adverse Events
Rates of adverse events from Operative Visit through Visit 5

Full Information

First Posted
July 3, 2023
Last Updated
July 3, 2023
Sponsor
VisionCare, Inc.
Collaborators
Wolfson Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05941273
Brief Title
A Study of the SING IMT in an Israeli Cohort
Official Title
A Study of the Implantable Miniature Telescope, Model SING (SING IMT) in Patients With Central Vision Impairment Associated With End-stage Age Related Macular Degeneration in an Israeli Cohort
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 30, 2023 (Anticipated)
Primary Completion Date
January 30, 2024 (Anticipated)
Study Completion Date
January 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VisionCare, Inc.
Collaborators
Wolfson Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this single center study is to determine the safety of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in a small sample of patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD) in an Israeli Cohort
Detailed Description
The SING IMT has CE Mark in the EU and has been implanted in over 200 patients globally including a pivotal study in the U.S. currently underway (the Concerto Study) and a post-marketing study in EU (The PMCF Study). Model SING is a new injectable model based on the IMT parent model (PMA P050034). Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with refraction, and also when using an external telescope simulator to determine if they are likely to benefit from receiving the SING IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery in one eye. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 10 rehabilitation/training visits with a low vision specialist to learn how to use the fellow eye for ambulation and the eye with the implant for magnified viewing during daily activities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Macular Degeneration, Geographic Atrophy
Keywords
Implantable Miniature Telescope

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single site case series
Masking
None (Open Label)
Masking Description
As the IMT has a unique appearance in the eye, it cannot be masked to the Investigator or to the patient
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Implanted Eye with SING IMT
Arm Type
Experimental
Arm Description
The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant
Intervention Type
Device
Intervention Name(s)
smaller incision, new generation implantable miniature telescope (SING-IMT)
Intervention Description
The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Primary Outcome Measure Information:
Title
Safety: Endothelial cell density
Description
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study
Time Frame
Comparison of baseline to Visit 5 (330 to 420 days post-operatively)
Secondary Outcome Measure Information:
Title
Adverse Events
Description
Rates of adverse events from Operative Visit through Visit 5
Time Frame
Approximately 12-months post-operatively (330-420 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For Both Eyes: Be at least 55 years of age at the Pre-operative Visit; Have ETDRS BCDVA 0.6 to 1.6 logMAR (20/80 to 20/800) at the Pre-operative Visit; Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by fluorescein angiography (FA) or OCT; Have an Endothelial Cell Density (ECD) above 1800 cells per millimeter; Have central anterior chamber depth (ACD) >2.5 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit; Agree to participate in post-operative visual training For the Implanted Eye: Have evidence of visually significant cataract at the Pre-operative Visit; Agree to undergo pre-operative assessment with low vision specialists (optometrist, occupational therapist or other professional with low vision experience) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment For the Non-Implanted Eye: -Have adequate peripheral vision at the Pre-operative Visit to allow navigation. Exclusion Criteria: For Both Eyes: Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training/rehabilitation with the device; Have evidence of bilateral active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months. Have any of the following conditions at the Pre-operative Visit: Stargardt macular dystrophy; Diabetic retinopathy; Untreated retinal tears; Retinal vascular disease; Optic nerve disease; History of retinal detachment; Intraocular tumor; Retinitis pigmentosa; History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit; Have known allergy to post-operative medications; History of eye rubbing or an ocular condition that predisposes subject to eye rubbing; Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit; Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety; Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study; Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit. For the Implanted Eye: Have a history of corneal stromal or endothelial dystrophies, including guttata; Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit; Have an Axial Length (AL) < 21 mm at the Pre-operative Visit; Have a narrow angle defined as < grade 2 on the Schaffer scale at the Pre-operative Visit; Ongoing Inflammatory ocular disease at the Pre-operative Visit; Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit; Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery; Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes; For the Non-Implanted Eye: -Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca Kammer, OD, PhD
Phone
+1(714)728-1575
Email
rkammer@samsaravision.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guy Kleinman, MD
Organizational Affiliation
Wolfson Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wolfson Medical Center
City
Holon
State/Province
Tel Aviv
ZIP/Postal Code
5822012
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guy Kleinman, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of the SING IMT in an Israeli Cohort

We'll reach out to this number within 24 hrs